
|Videos|October 3, 2020
HER2-targeted Therapy: Routes of Administration
Author(s)Staff
Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management of HER2+ breast cancer and examining the potential use of at-home administration.
Advertisement
Evaluating the benefits of the subQ vs IV formulation of the trastuzumab-pertuzumab combination for the management of HER2+ breast cancer and examining the potential use of at-home administration.
Advertisement
Advertisement
Advertisement
Trending on Oncology Nursing News
1
AI and Oncology Nursing: Detecting Misdiagnosis With Molecular Profiling
2
FDA Approves Gedatolisib for HR+/HER2- Advanced Breast Cancer: What Nurses Need to Know
3
FDA Grants Traditional Approval to Selpercatinib for RET-Fusion Solid Tumors
4
Optimizing Multiple Myeloma Care: Insights From a Nursing Expert
5




























































